Sanofi's Multaq hits another setback
This article was originally published in Scrip
Executive Summary
Sanofi has halted the Phase IIIb PALLAS study of its anti-arrhythmic Multaq (dronedarone) in the additional treatment setting of permanent atrial fibrillation (AF) on safety concerns.